594 related articles for article (PubMed ID: 22766356)
41. Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors.
Jean MJ; Fiches G; Hayashi T; Zhu J
AIDS Res Hum Retroviruses; 2019 Jan; 35(1):1-24. PubMed ID: 30351168
[TBL] [Abstract][Full Text] [Related]
42. Epigenetic regulation of HIV-1 persistence and evolving strategies for virus eradication.
Dhamija N; Rawat P; Mitra D
Subcell Biochem; 2013; 61():479-505. PubMed ID: 23150264
[TBL] [Abstract][Full Text] [Related]
43. The Effect of JAK1/2 Inhibitors on HIV Reservoir Using Primary Lymphoid Cell Model of HIV Latency.
de Armas LR; Gavegnano C; Pallikkuth S; Rinaldi S; Pan L; Battivelli E; Verdin E; Younis RT; Pahwa R; Williams SL; Schinazi RF; Pahwa S
Front Immunol; 2021; 12():720697. PubMed ID: 34531866
[TBL] [Abstract][Full Text] [Related]
44. Underlying mechanisms of HIV-1 latency.
Romani B; Allahbakhshi E
Virus Genes; 2017 Jun; 53(3):329-339. PubMed ID: 28258391
[TBL] [Abstract][Full Text] [Related]
45. Oxaliplatin antagonizes HIV-1 latency by activating NF-κB without causing global T cell activation.
Zhu X; Liu S; Wang P; Qu X; Wang X; Zeng H; Chen H; Zhu H
Biochem Biophys Res Commun; 2014 Jul; 450(1):202-7. PubMed ID: 24878527
[TBL] [Abstract][Full Text] [Related]
46. Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency Reversal.
Stoszko M; De Crignis E; Rokx C; Khalid MM; Lungu C; Palstra RJ; Kan TW; Boucher C; Verbon A; Dykhuizen EC; Mahmoudi T
EBioMedicine; 2016 Jan; 3():108-121. PubMed ID: 26870822
[TBL] [Abstract][Full Text] [Related]
47. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
Elliott JH; Wightman F; Solomon A; Ghneim K; Ahlers J; Cameron MJ; Smith MZ; Spelman T; McMahon J; Velayudham P; Brown G; Roney J; Watson J; Prince MH; Hoy JF; Chomont N; Fromentin R; Procopio FA; Zeidan J; Palmer S; Odevall L; Johnstone RW; Martin BP; Sinclair E; Deeks SG; Hazuda DJ; Cameron PU; Sékaly RP; Lewin SR
PLoS Pathog; 2014 Oct; 10(10):e1004473. PubMed ID: 25393648
[TBL] [Abstract][Full Text] [Related]
48. Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells.
Choudhary SK; Archin NM; Margolis DM
J Infect Dis; 2008 Apr; 197(8):1162-70. PubMed ID: 18419522
[TBL] [Abstract][Full Text] [Related]
49. Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies.
Demonté D; Quivy V; Colette Y; Van Lint C
Biochem Pharmacol; 2004 Sep; 68(6):1231-8. PubMed ID: 15313421
[TBL] [Abstract][Full Text] [Related]
50. Effects of diterpenes from latex of Euphorbia lactea and Euphorbia laurifolia on human immunodeficiency virus type 1 reactivation.
Avila L; Perez M; Sanchez-Duffhues G; Hernández-Galán R; Muñoz E; Cabezas F; Quiñones W; Torres F; Echeverri F
Phytochemistry; 2010 Feb; 71(2-3):243-8. PubMed ID: 19897215
[TBL] [Abstract][Full Text] [Related]
51. TLR5 stimulation is sufficient to trigger reactivation of latent HIV-1 provirus in T lymphoid cells and activate virus gene expression in central memory CD4+ T cells.
Thibault S; Imbeault M; Tardif MR; Tremblay MJ
Virology; 2009 Jun; 389(1-2):20-5. PubMed ID: 19447460
[TBL] [Abstract][Full Text] [Related]
52. [Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects].
Marcello A; Giacca M
Pathologica; 2000 Aug; 92(4):291-3. PubMed ID: 11029891
[No Abstract] [Full Text] [Related]
53. Latency: the hidden HIV-1 challenge.
Marcello A
Retrovirology; 2006 Jan; 3():7. PubMed ID: 16412247
[TBL] [Abstract][Full Text] [Related]
54. In vitro reactivation of human immunodeficiency virus 1 from latently infected, resting CD4+ T cells after bacterial stimulation.
Moriuchi H; Moriuchi M; Mizell SB; Ehler LA; Fauci AS
J Infect Dis; 2000 Jun; 181(6):2041-4. PubMed ID: 10837189
[TBL] [Abstract][Full Text] [Related]
55. Compounds producing an effective combinatorial regimen for disruption of HIV-1 latency.
Hashemi P; Barreto K; Bernhard W; Lomness A; Honson N; Pfeifer TA; Harrigan PR; Sadowski I
EMBO Mol Med; 2018 Feb; 10(2):160-174. PubMed ID: 29246970
[TBL] [Abstract][Full Text] [Related]
56. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure.
Chun TW; Fauci AS
AIDS; 2012 Jun; 26(10):1261-8. PubMed ID: 22472858
[TBL] [Abstract][Full Text] [Related]
57. Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.
Euler Z; Alter G
AIDS Res Hum Retroviruses; 2015 Jan; 31(1):13-24. PubMed ID: 25385703
[TBL] [Abstract][Full Text] [Related]
58. Targeting the Latent Reservoir for HIV-1.
Sengupta S; Siliciano RF
Immunity; 2018 May; 48(5):872-895. PubMed ID: 29768175
[TBL] [Abstract][Full Text] [Related]
59. Potential of Radiation-Induced Cellular Stress for Reactivation of Latent HIV-1 and Killing of Infected Cells.
Iordanskiy S; Kashanchi F
AIDS Res Hum Retroviruses; 2016 Feb; 32(2):120-4. PubMed ID: 26765533
[TBL] [Abstract][Full Text] [Related]
60. Histone deacetylase inhibitors containing a benzamide functional group and a pyridyl cap are preferentially effective human immunodeficiency virus-1 latency-reversing agents in primary resting CD4+ T cells.
Kobayashi Y; Gélinas C; Dougherty JP
J Gen Virol; 2017 Apr; 98(4):799-809. PubMed ID: 28113052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
